|1.||Soga, S: 2 articles (12/2001 - 12/2001)|
|2.||Akinaga, S: 2 articles (12/2001 - 12/2001)|
|3.||Kurebayashi, J: 2 articles (12/2001 - 12/2001)|
|4.||Kurosumi, M: 1 article (12/2001)|
|5.||Ikuina, Y: 1 article (12/2001)|
|6.||Tamaoki, T: 1 article (12/2001)|
|7.||Murakata, C: 1 article (12/2001)|
|8.||Neckers, L M: 1 article (12/2001)|
|9.||Schulte, T W: 1 article (12/2001)|
|10.||Yamaguchi, K: 1 article (12/2001)|
|1.||Breast Neoplasms (Breast Cancer)
12/01/2001 - "KF58333 showed potent antiproliferative activity against all breast cancer cell lines tested in vitro, and was more potent than its stereoisomer KF58332. "
12/01/2001 - "Interestingly, KF58333, but not KF58332, showed significant in vivo antitumor activity accompanied by induction of apoptosis in KPL-4 human breast cancer xenografts. "
12/01/2001 - "A radicicol derivative, KF58333, inhibits expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts."
12/01/2001 - "These results suggest that inhibition of hsp90 function, which causes depletion of hsp90 client proteins in tumor, contributes to the antitumor activity of KF58333, and that the stereochemistry of the oxime moiety is important for the biological activity of radicicol oxime derivatives."
12/01/2001 - "Although the plasma concentrations of these compounds were equivalent, KF58333, but not KF58332, depleted hsp90 client proteins such as erbB2, raf-1 and Akt in the tumor specimen recovered from nude mice. "
|2.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|3.||Proteins (Proteins, Gene)
|1.||Heterologous Transplantation (Xenotransplantation)